Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
H.C. Wainwright Downgrades Fate Therapeutics (FATE) to Neutral
March 6, 2018 7:57 AM ESTH.C. Wainwright downgraded Fate Therapeutics (NASDAQ: FATE) from Buy to Neutral with a price target of $12.00 (from $7.00).
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $13.77 yesterday.
... MoreFate Therapeutics (FATE) Misses Q4 EPS by 5c
March 5, 2018 4:04 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.29), $0.05 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $940 thousand.
Cash, cash equivalents and short-term investments as of December 31, 2017 were $100.9 million compared to $92.1 million as of... More
